KROS Company Profile and Key Details

Keros Therapeutics, Inc. has 40.62 million shares outstanding. The public float is 27.23 million shares, elevated short interest at 18.67% of float. This equals 4.84 million shares. The short ratio is 10.81 days. Institutional investors hold 103.46% of the float. Insiders own 2.73%. Seehra Jasbir holds 385.71 thousand shares, Knowles Julius has 232.73 thousand shares and ORBIMED ADVISORS LLC has 119.52 thousand shares. Over the past six months, insider transactions show net selling. They sold 918.99 thousand shares across 6 transactions.

Short-term trend indicators are mixed aligned (SMA20 -10.92%, SMA50 -18.8%, SMA200 -6.63%). The stock’s 14-day RSI is 25.38 (weak momentum), while the ATR of 0.65 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -33.35% below its high and over 64.8% above its low. Average 10-day trading volume of 537.00 thousand shares is slightly above the 3-month average of 395.40 thousand, indicating heightened recent market interest.

Keros Therapeutics, Inc. generated EPS of $1.54 over the past year. Five-year average earnings growth is -48.13%. Wall Street analysts project EPS growth of 5.51% annually over the next five years. The latest quarter delivered EPS of -$0.18. The next quarter is forecast at -$0.70. Next year's EPS is expected at -$3.63. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 3 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $15.00. The high target offers 245.42% upside. The low target suggests 29.53% downside. The mean target is $23.11. This offers 99.57% upside. Keros Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -83.78%. The prior quarter beat by -33.33%. Over the last six quarters, Apple has recorded several small beats. These include 1.63% in August 07, 2024.

Keros Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $13.65. This means the shares are trading below this model’s fair value.

Keros Therapeutics, Inc. (NASDAQ:KROS) closed at $11.58 USD, gaining $0.23 (2.03%) from the previous close of $11.35. The stock is currently mid-range between its 52-week high and low $9.12 and $22.55. With a market capitalization of about $431.02 million, Keros Therapeutics, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.90). Key stats such as the average daily volume over the past year has been around 400.96 thousand shares, trading with heavier-than-usual volume. Headquartered in Lexington, MA, Keros Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jasbir S. Seehra, the company employs approximately 163 people and listed since April 08, 2020. Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need.

Keros Therapeutics, Inc. (NASDAQ:KROS) shares are flat -9.48% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Keros Therapeutics, Inc. trading at a premium to the broader market with a P/E of 4.9. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $63.93, suggesting 452.07% upside. Our AI forecast model points to short-term weakness (-29.27% over two weeks), a medium-term rise (1080.4% over three months), and a longer-term loss (-17.79% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Keros Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -29.27%, with price expected at $8.19 by March 23, 2026, within a range of $7.79 to $8.61 3-Month Outlook: Projected rise of 1080.4%, reaching $136.69 by June 05, 2026, with a range of $135.02 to $139.26. 1-Year Outlook: Projected loss of -17.79%, with price at $9.52 by March 09, 2027, within a range of $0.00 to $14.35.

Keros Therapeutics, Inc. trades at a P/E ratio of 4.9, slightly below the S&P 500 average, with a price-to-sales ratio of 1.75 and a price-to-book ratio of 1.41 suggesting the stock is closer to book value. The P/FCF stands at 4.03, also above market averages.